6-12F (15F max outer diameter) Venous Closure
The only FDA-approved closure device for use following cardiac ablations*
Proven
Proven by EPs in the ambulate pivotal trial
VASCADE MVP was evaluated in the AMBULATE pivotal trial. AMBULATE was a multicenter, randomized clinical trial with 204 patients randomized 1:1 to VASCADE MVP or manual compression.
Opioid Use1
Number of Patients Receiving Opioids Post-Procedure
Manual Comp = 37 pts
VASCADE MVP = 15 pts
Patient Satisfaction with Duration of Bedrest
Comparison to Bedrest from a Previous Cardiac Ablation Procedure
Manual Comp = 5.6 vs.
VASCADE MVP = 7.9 mean
All Patients
Manual Comp = 5.1 vs.
VASCADE MVP = 8.3 mean
1 As demonstrated in the AMBULATE Pivotal Trial. | * Cardiac ablations requiring two or more access sites within the same limb. See VASCADE MVP IFU 3972 Indications for Use
VASCADE MVP® Videos and Literature
